Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19

This article has been Reviewed by the following groups

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Azithromycin is a widely used antibiotic and was frequently used to treat hospitalized patients during the COVID-19 pandemic. The impact of empiric azithromycin use on the respiratory microbiome in patients with viral respiratory infections is unclear. Here we used longitudinal metatranscriptomics on nasal swabs from a prospective multicentre cohort of 1,164 patients hospitalized for COVID-19. We compared the upper respiratory microbiome, resistome and systemic immune response in patients treated with azithromycin ( n  = 366) with those who received no antibiotics ( n  = 474) or other antibiotics ( n  = 324). We found that azithromycin altered microbiome composition and increased the expression and relative proportion of macrolide/lincosamide/streptogramin (MLS) resistance genes. These changes occurred after 1 day of exposure and persisted for over a week. MLS resistance gene expression was associated with commensals and potential pathogens, while there were no differences in host inflammatory gene expression in blood and airways. This demonstrates that empiric azithromycin treatment impacts the upper respiratory microbiome and resistome without apparent anti-inflammatory benefit.

Article activity feed

  1. Longitudinal metatranscriptomics in a cohort of 1,164 adults hospitalized for COVID-19 reveals that azithromycin offered no apparent anti-inflammatory benefit but enriched the respiratory microbiome with potential pathogens and antimicrobial resistance genes. www.nature.com/articles/s41...

  2. Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19 www.nature.com/articles/s41...

  3. Lessons still being learnt from the COVID19 pandemic 💡 🦠 While it was widely used in hospitalised patients, Azithromycin didn't offer a significant anti-inflammatory benefit but enriched the respiratory microbiome with potential pathogens and AMR genes. #MicroSky www.nature.com/articles/s41...

  4. Antibiotici azithromycin was frequently used to treat hospitalized COVID-19 patients and here is shown to impacts the upper respiratory microbiome and resistome without apparent anti-inflammatory benefit www.nature.com/articles/s41... @natmicrobiol.nature.com @czbiohub.bsky.social

  5. Wow wow! How this could be?? )) Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19. Glascock A., et al. Nat Microbiol, 2026. doi.org/10.1038/s415...

  6. Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19 ->Nature | More on "Azithromycin microbiome COVID-19 antibiotic resistance" at BigEarthData.ai | #Microbiome #Covid19 #SoilHealth

  7. In a US study of 1164 hospitalized COVID-19 patients, azithromycin use changed the airway microbiome, boosted macrolide resistance genes, and showed no anti-inflammatory benefit. Its routine use may worsen antibiotic resistance without helping. www.researchsquare.com/article/rs-6...